This analysis affirms Tdap's favorable safety profile while detecting statistically significant signals that merit additional research. The low absolute risk supports continued maternal immunization, but warrants enhanced monitoring in high-risk pregnancies. The findings highlight the importance of ongoing post-marketing surveillance for evaluating vaccine safety in pregnant populations and contribute to evidence-based decision-making in clinical practice and public health policy.
Fan et al. (Tue,) studied this question.